Major trial indicates potential of novel hypertension drug
New clinical data suggest potential for the first targeted aldosterone synthase inhibitor to treat uncontrolled or resistant hypertension.
New treatment for adults with acute lymphoblastic leukaemia
EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Aucatzyl (obecabtagene autoleucel) to treat adults from 26 years of age with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (B ALL).
EMA starts review of ipidacrine-containing medicines
EMA’s human medicines committee (CHMP) has started a review of medicines containing ipidacrine. These medicines have been authorised in several EU countries through national procedures and are used in adults to treat different conditions affecting the nervous system.
Draft Guidance on Replacing Color Additives in Approved or Marketed Drugs
U.S. Food and Drug Administration issued a draft guidance providing drug manufacturers with recommendations on replacing color additives in drugs.